Hostname: page-component-6766d58669-76mfw Total loading time: 0 Render date: 2026-05-15T22:38:20.578Z Has data issue: false hasContentIssue false

Improvement of insulin resistance after diet with a whole-grain based dietary product: results of a randomized, controlled cross-over study in obese subjects with elevated fasting blood glucose

Published online by Cambridge University Press:  01 November 2007

Klaus Rave
Affiliation:
Profil Institut für Stoffwechselforschung GmbH, Hellersbergstr. 9, 41460 Neuss, Germany
Kerstin Roggen*
Affiliation:
Profil Institut für Stoffwechselforschung GmbH, Hellersbergstr. 9, 41460 Neuss, Germany
Sibylle Dellweg
Affiliation:
Profil Institut für Stoffwechselforschung GmbH, Hellersbergstr. 9, 41460 Neuss, Germany
Tim Heise
Affiliation:
Profil Institut für Stoffwechselforschung GmbH, Hellersbergstr. 9, 41460 Neuss, Germany
Heike tom Dieck
Affiliation:
Cargill GmbH, Lise-Meitner-Strasse 34, 85354 Freising, Germany
*
*Corresponding author: Kerstin Roggen, Ph.D., fax +49 (2131) 4018-518, email kerstin.roggen@profil-research.de
Rights & Permissions [Opens in a new window]

Abstract

Subjects with obesity and elevated fasting blood glucose are at high risk of developing type 2 diabetes which may be reduced by a dietary intervention leading to an improvement of insulin resistance. We investigated the potential of a whole-grain based dietary product (WG) with reduced starch content derived from double-fermented wheat during a hypo-energetic diet to positively influence body weight, fasting blood glucose, insulin resistance and lipids in comparison to a nutrient-dense meal replacement product (MR) in a randomized two-way cross-over study with two 4-week treatment periods separated by a 2-week wash-out. Subjects replaced at least two daily meals with WG and MR, respectively, targeting for a consumption of 200 g of either product per day. Total daily energy intake was limited to 7120 kJ. Thirty-one subjects (BMI 33·9 (sd 2·7) kg/m2, fasting blood glucose 6·3 (sd 0·8) mmol/l) completed the study. In both treatment groups body weight ( − 2·5 (sd 2·0) v. − 3·2 (sd 1·6) kg for WG v. MR), fasting blood glucose ( − 0·4 (sd 0·3) v. − 0·5 (sd 0·5) mmol/l), total cholesterol ( − 0·5 (sd 0·5) v. − 0·6 (sd 0·5) mmol/l), TAG ( − 0·3 (sd 0·9) v. − 0·3 (sd 1·2) mmol/l) and homeostasis model assessment (HOMA) insulin resistance score ( − 0·7 (sd 0·8) v. − 1·1 (sd 1·7) μU/ml ×  mmol/l) improved (P < 0·05) with no significant differences between the treatments. After statistical adjustment for the amount of body weight lost, however, the comparison between both groups revealed that fasting serum insulin (P = 0·031) and HOMA insulin resistance score (P = 0·049) improved better with WG than with MR. We conclude that WG favourably influences metabolic risk factors for type 2 diabetes independent from the amount of body weight lost during a hypo-energetic diet.

Information

Type
Full Papers
Copyright
Copyright © The Authors 2007
Figure 0

Table 1 Nutritional values of the whole-grain based dietary product (WG) and the nutrient-dense meal replacement product (MR)

Figure 1

Table 2 Baseline characteristics and changes (Δ) from baseline after 4 weeks of diet with a whole-grain based dietary product (WG) and a meal replacement product (MR) in thirty-one obese subjects with elevated fasting blood glucose

Figure 2

Fig. 1 Course of body weight during the study. ○, Subjects randomized to treatment sequence whole-grain based dietary product (WG) / meal replacement product (MR); ●, subjects randomized to treatment sequence MR / WG.

Figure 3

Fig. 2 (A) Fasting blood glucose, (B) homeostasis model assessment insulin resistance (HOMA-IR), and (C) total cholesterol before () and after (□) diet with a whole-grain based dietary product (WG) and a meal replacement product (MR). Mean value was significant different from baseline value after adjustment for the amount of body weight lost *P < 0·05.

Figure 4

Table 3 Mean baseline characteristics and changes (Δ) from baseline after 4 weeks of diet with a whole-grain based dietary product (WG) or a meal replacement product (MR) after statistical adjustment for the amount of body weight lost in thirty-one obese subjects with elevated fasting blood glucose

Figure 5

Table 4 Gastrointestinal adverse events